RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more
RAPT Therapeutics Inc (RAPT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.082x
Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) has a cash flow conversion efficiency ratio of -0.082x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.46 Million) by net assets ($151.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RAPT Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how RAPT Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
RAPT Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RAPT Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Astec Industries Inc
NASDAQ:ASTE
|
0.052x |
|
Berkshire Hills Bancorp Inc
NYSE:BHLB
|
0.032x |
|
Jiangsu Broadcasting Cable inf
SHG:600959
|
0.005x |
|
PT Perusahaan Gas Negara Tbk
F:PGB1
|
0.032x |
|
Bozhon Precision Industry Technology Co. Ltd. A
SHG:688097
|
0.085x |
|
Wangfujing
SHG:600859
|
0.035x |
|
Husqvarna AB Series A
LSE:0GWI
|
0.033x |
|
Keller Group plc
PINK:KLRGF
|
0.199x |
Annual Cash Flow Conversion Efficiency for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of RAPT Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $189.90 Million | $-83.30 Million | -0.439x | +33.54% |
| 2023-12-31 | $147.03 Million | $-97.05 Million | -0.660x | -128.65% |
| 2022-12-31 | $245.17 Million | $-70.77 Million | -0.289x | +11.84% |
| 2021-12-31 | $186.38 Million | $-61.03 Million | -0.327x | +15.76% |
| 2020-12-31 | $104.18 Million | $-40.49 Million | -0.389x | +19.89% |
| 2019-12-31 | $73.12 Million | $-35.47 Million | -0.485x | +5.78% |
| 2018-12-31 | $64.00 Million | $-32.95 Million | -0.515x | -218.47% |
| 2017-12-31 | $-62.41 Million | $-27.12 Million | 0.435x | -- |